3rd Quarter - Report

EMERGENT BIOSOLUTIONS INC. for EMERGENT BIOSOLUTIONS INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$590,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 16, 2009 $590,000 Replaced
3rd Quarter - Report Jan 20, 2010 $680,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Homeland Security HOM

P.L. 115-5 - American Recovery & Reinvestment Act of 2009 - implementation of provisions relating to biodefense funding; H.R. 3293 - Department of Labor, Health & Human Services and Education Appropriations Act for 2010 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. H.R. 2892 - Department of Homeland Security Appropriations Act 2010 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. S1649 - WMD Prevention and Preparedness Act of 2009 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project Bioshield relating to stockpiling of biodefense vaccines.

LobbyistCovered position, as disclosed
ASHLEY BRATICH —
CHRIS FRECH —
ALLEN SHOFE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2892 (111th), H.R. 3293 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.